|
More Smart Savings From ASHP Meeting
Pharmacy Practice News That means that, in many cases, recipients require higher levels of induction agents, such as antithymocyte globulin (ATG) and basiliximab (Siumulect, Novartis) than those who receive nonmarginal kidneys. “When you combine the high cost of these drugs … |
|
‘New Technologies to Capture Over 10% of the Antibody Therapeutics Market by …
EIN News (press release) You can see Roche getting in on the ground floor there with what they’re doing with obinituzumab and T-DM1, using engineering and ADC technologies to extend their rituximab and trastuzumab franchises. T-DM1 is potentially a major watershed for the … |
Meds from foreign plants complicate counterfeit searchFiercePharma ManufacturingOne of the drugs the center bought was rituximab, the foreign version of the cancer drug sold as Rituxan in the U.S. Investigators found that it was manufactured at a Roche…
 Genetic Engineering News |
Literature Review: ELISA—Detected Through A Quick Glance
Genetic Engineering News In sandwich ELISA, the target molecule is anchored to the substrate by capture antibodies and recognized by primary antibodies. In the present work, the enzyme is linked to the immunocomplex through interactions between enzyme-decorated streptavidin … |
One Million Americans with Blood Cancer in Jeopardy of Losing Access to …Sacramento BeeSome of these include therapies for patients with chronic myelogenous leukemia such as imatinib, dastatinib, bosutinib, nilotinib and ponatinib; lenalidomide and t…
|
신장 이식 환자에서 mTOR 억제제 기반의 면역 억제 요법
청년의사 피험자 전원은 스테로이드와 함께 유도 요법으로 basiliximab을 투여 받았으며, 연구진은 두 군의 BPAR, 이식편 소실, 사망, 추적관찰 소실, 신기능(eGFR), 이상반응 발생률을 비교하였다. 이식 환자의 연령, 성별, HLA-부적합, 투석 여부, 동반 질환은 두 군 간 유 … |
Clinical Oncology NewsClinical Hematologic Review: Highlights from ASH and NEJM, JCO and BloodClinical Oncology NewsInvestigators from MD Anderson Cancer Center presented encouraging Phase II data showing ibrutinib (PCI-32765, Janssen) in combination w…
One Million Americans with Blood Cancer in Jeopardy of Losing Access to …PR Newswire (press release)Some of these include therapies for patients with chronic myelogenous leukemia such as imatinib, dastatinib, bosutinib, nilotinib and ponatinib; lenal…
2 antibodies are better than 1Science CodexWe allow third-party companies to serve ads and/or collect anonymous information. These companies may use non-personally identifiable information (browser type, time and date) in order to provide advertisement…
Postcardiac transplant survival in the current era in patients receiving …The Journal of Thoracic and Cardiovascular SurgeryIf the patient had renal dysfunction (glomerular filtration rate <30 mL/min/1.73 m2) for 3 days after transplantation, an i…